Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Paliperidone ER in Treatment-Naïve and Newly Diagnosed Schizophrenia
NCT01606228Phase 3Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Dec 2007
- Primary completion
- Dec 2008
- Modality
- Small Molecules
01
Overview
Phase 3, open-label, single-arm trial of paliperidone in schizophrenia, sponsored by Janssen Pharmaceutical. Primary endpoint: Proportion of Patients Improving 20% in Total Positive and Negative Syndrome Scale (PANSS) at Day 90. Started Dec 2007; status: completed.
02
Drugs
paliperidone
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT01606228.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01606228.